Daniel Patrick O'Day
Chairman & CEO at Gilead Sciences Inc. · b. 1964
Sits on 1 board. Last updated September 28, 2026
Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 4 years
- Director since
- 2023
4 years of board service in total across 1 board, counting each seat separately. Longest: Gilead Sciences Inc., 3 years.
Chief executive roles
Solid · grade C
Out of 100, from shareholder return, dividends, growth and acquisitions.
Partial: only 50% of the scoring weight is on file.
- Dividends 15%
- 67
- Revenue growth 20%
- 58
- Earnings growth 15%
- 69
dividend grew 4.8% a year
4.2% a year in revenue
7.2% a year in earnings per share
50% of the scoring weight is on file. Figures cover December 2018 – December 2025.
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Gilead Sciences Inc. April 30, 202695.1%
-
Gilead Sciences Inc. May 7, 202593.8%
-
Gilead Sciences Inc. May 8, 202493.7%
-
Gilead Sciences Inc. May 3, 202392.9%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Nov 5, 2026 | Gilead Sciences Inc. | Option exercise | +9,810 | $72.34 | $709,655 |
| Nov 5, 2026 | Gilead Sciences Inc. | Open-market sale | −9,810 | $175.17 | $1,718,418 |
| Nov 4, 2026 | Gilead Sciences Inc. | Option exercise | +102,619 | $72.34 | $7,423,458 |
| Nov 4, 2026 | Gilead Sciences Inc. | Open-market sale | −102,619 | $175.16 | $17,975,021 |
| Nov 2, 2026 | Gilead Sciences Inc. | Open-market sale | −1,600 | $167.40 | $267,840 |
| Nov 2, 2026 | Gilead Sciences Inc. | Open-market sale | −1,700 | $168.10 | $285,771 |
| Nov 2, 2026 | Gilead Sciences Inc. | Open-market sale | −1,904 | $169.27 | $322,296 |
| Nov 2, 2026 | Gilead Sciences Inc. | Open-market sale | −7,796 | $170.35 | $1,328,070 |
| Nov 2, 2026 | Gilead Sciences Inc. | Open-market sale | −2,000 | $171.06 | $342,125 |
| Oct 30, 2026 | Gilead Sciences Inc. | Option exercise | +15,881 | $72.34 | $1,148,832 |
| Oct 30, 2026 | Gilead Sciences Inc. | Open-market sale | −15,881 | $175.25 | $2,783,075 |
| Oct 1, 2026 | Gilead Sciences Inc. | Open-market sale | −12,000 | $147.72 | $1,772,628 |
| Oct 1, 2026 | Gilead Sciences Inc. | Open-market sale | −3,000 | $148.63 | $445,880 |
| Sep 10, 2026 | Gilead Sciences Inc. | Option exercise | +8,780 | — | — |
| Sep 10, 2026 | Gilead Sciences Inc. | Shares withheld for tax | −4,230 | $144.81 | $612,546 |
Questions about Daniel Patrick O'Day
What boards is Daniel Patrick O'Day on?
Daniel Patrick O'Day sits on the board of Gilead Sciences Inc.
What company is Daniel Patrick O'Day the CEO of?
Daniel Patrick O'Day has been Chairman & CEO of Gilead Sciences Inc. since March 2019.
How long has Daniel Patrick O'Day served on boards?
Our records show at least 4 years of board service across 1 board, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.